Tel Aviv, Israel | May 3, 2026
Everads Therapy has announced the publication of first-in-human clinical data for its novel suprachoroidal injector, demonstrating favorable safety, tolerability, and device performance in patients with diabetic macular edema (DME). The study, published in Ophthalmology Science, highlights the potential of this next-generation ocular drug delivery technology to enable targeted, posteriorly directed drug distribution, marking a significant advancement in the treatment of retinal diseases.
First-in-Human Data Demonstrates Safety and Feasibility
The open-label clinical trial (NCT06314217) evaluated the use of the Everads Injector for suprachoroidal administration of triamcinolone acetonide suspension in patients with DME. The results confirmed a strong safety and tolerability profile, along with procedural feasibility and ease of use in an office-based setting, supporting its potential integration into routine clinical practice.
Importantly, the study demonstrated that the device enables controlled and consistent access to the suprachoroidal space, a promising route for delivering therapeutics directly to the posterior segment of the eye, where many retinal diseases originate. This approach addresses limitations associated with traditional intravitreal injections, which may not achieve optimal drug distribution.
The findings represent a critical milestone for Everads, as first-in-human clinical validation is a key step in advancing innovative medical technologies through GxP-compliant development pathways.
Advertisement
Innovative Delivery Enables Targeted Drug Distribution
A standout feature of the Everads Injector is its ability to achieve rapid, posteriorly directed drug distribution, as visualized using real-time thermal imaging techniques. This capability allows for precise targeting of the macular region, which is essential in conditions such as diabetic macular edema and other retinal disorders.
The device utilizes a proprietary non-sharp tissue separator, enabling non-surgical, minimally invasive access to the suprachoroidal space through controlled tissue separation. This design reduces procedural complexity while improving patient comfort and clinical efficiency.
By facilitating broad and targeted drug distribution, the technology has the potential to enhance the effectiveness of a wide range of therapies, including small molecules, gene therapies, and cell-based treatments, positioning it as a versatile platform in ophthalmology.
Expanding Clinical and Scientific Validation at ARVO 2026
Building on its clinical publication, Everads is presenting three scientific studies at the ARVO 2026 Annual Meeting, further validating its suprachoroidal delivery platform. These presentations highlight real-time infrared thermography for confirming drug delivery, as well as methods for differentiating suprachoroidal versus intravitreal injection patterns.
The data reinforce the platform’s ability to deliver consistent and reproducible therapeutic distribution, supporting its potential adoption in both clinical and research settings. As interest in suprachoroidal delivery continues to grow, the need for safe, reliable, and scalable delivery systems becomes increasingly important.
Everads’ technology is designed to meet this demand, enabling in-office administration without the need for surgical intervention, which could significantly expand patient access to advanced retinal therapies.
The publication of first-in-human data for the Everads Injector marks a major advancement in ophthalmic drug delivery, demonstrating its potential to improve therapeutic targeting and patient outcomes in retinal diseases. With strong clinical validation and ongoing scientific engagement at ARVO 2026, Everads Therapy is positioning itself at the forefront of MedTech innovation, advancing a next-generation platform that could redefine how retinal therapies are delivered and administered.
Source: Everads Therapy press release
